The Future of Biotechnology

Life-Changing INNOVATIONS

THE FUTURE OF BIOTECHNOLOGY, MEDIPOST

CONTINUE ON SITE

Latest News

MEDIPOST Enhances its Partnership with Canada’s OmniaBio in Collaboration for the CMDO Business of OmniaBio’s All-Around Cell and Gene Therapy.

2022/12/01

Medipost to launch a CDMO business for cell and gene therapy products in Korea based on 20 years of research and production knowledge

2022/10/17

Canada’s OmniaBio, MEDIPOST affiliate begins CDMO cGMP for cell gene therapy

2022/10/07

MEDIPOST’s 5-year follow-up of phase 3 clinical trial patients receives 2021 OJSM award

2022/07/18

Medipost enters North American market by acquiring OmniaBio, a CDMO company with cell and gene therapy products

2022/05/31

MEDIPOST GMP Cell Manufacturing Facility

MEDIPOST gears up to enter the global SMUP-IA-01 market based on clinical results in Korea

2022/04/01

MEDIPOST’s treatment for knee osteoarthritis, enters phase 3 clinical trials in Japan

2022/03/25

MEDIPOST enters into new business and accelerates its clinical trials in the U.S. through third-party allotment financing

2022/03/17

VIEW MORE NEWS

Global Leader
in Stem Cell Therapeutics

Number of registered patents in Korea and overseas

Number of national R&D grants received in Korea

Number of private cord blood units stored

Percentage of R&D staff

1^st Generation Cord Blood-derived Stem Cell Products

CARTISTEM^®

Treatment of knee cartilage defects including for patients with Knee Osteoarthritis

CARTISTEM^® – allogeneic umbilical cord blood-derived mesenchymal stem cells, is used for the treatment of knee cartilage defects in patients with Osteoarthritis (with ICRS grade* IV cartilage defect) caused by degeneration or repetitive trauma.

PNEUMOSTEM^®

Preventive treatment of bronchopulmonary dysplasia(BPD)

PNEUMOSTEM^® an allogeneic umbilical cord blood-derived mesenchymal stem cell product, is currently under development for the preventive treatment of Bronchopulmonary Dysplasia(BPD) in premature infants. Currently, Phase 2 clinical trial is ongoing in Korea and PNEUMOSTEM^® has been Orphan Drug designated by US FDA and EMA. Recently, US FDA granted a Fast Track Designation for PNEUMOSTEM^®.

2^nd Generation Cord Blood-derived Stem Cell Products

SMUP-IA-01

Intra-articular Injectable treatment for osteoarthritis

SMUP-IA-01, SMUP allogeneic umbilical cord blood-derived mesenchymal stem cells, is currently under development for the treatment and prevention of Osteoarthritis. Currently, SMUP-IA-01 is undergoing Phase 2 clinical trial in Korea with IND from the MFDS.

SMUP-IV-01

Intra-venous infusion treatment for diabetic nephropathy

SMUP-IV-01, an SMUP allogeneic umbilical cord blood-derived mesenchymal stem cels, is under development for the treatment and prevention of Diabetic Nephropathy. Currently, SMUP-IV-01 is in the process of applying for phase 1 clinical trial of the MFDS.

Development status

Global Leader in Stem Cell Therapeutics

As a global leader in biotechnology with cutting-edge Technologies in Stem Cell Therapeutics, MEDIPOST continues to innovate and challenge to tackle unmet medical needs.

About Us INVESTOR RELATIONS